Gyg Share Discussion Threads

[johnroger] 21/9/2004 14:00

LONDON (AFX) - Gyrus Group PLC said it is on track to deliver expectations
for the full year after a good start to the secpnd half of the year, as it
announced a rise in pretax profits for the first half despite the negative
impact of the US dollar.
The group, which supplies medical devices that reduce trauma and
complications in surgery, said that they remain confident in their ability to
achieve "high teens" growth targets in the medium term.
For the six months ended 30 June 2004, Gyrus said that underlying profit
before tax and goodwill amortisation came in at 3.7 mln stg, compared with 3.0
mln stg in the same period of the year before.
Revenues in the period were 14 pct higher at 42.5 mln stg, against 37.2 mln
stg, while adjusted EPS (before goodwill) was 4.1 pence, up from 3.7 pence.
"To have achieved such strong revenue and profit growth despite the weakness
of the dollar is a major achievement and evidence of the strength of our
business model," Brian Steer, Executive Chairman commented.
"We are continuing to benefit from the changes implemented last year and
remain confident in our ability to achieve our "high teens" revenue growth and
profitability targets in the medium term."
[e-mail]

At first glance the results look good but the price is unmoved

[zapa] 15/9/2004 19:39

Buy a 'racy' share.

[maddox] 15/9/2004 18:32

Thanks Johnroger,

Always interested to see the TA prespective. It would be nice to see GYG settle into a higher trading range - all this sideways movement is so boring.

Regards, Maddox

[johnroger] 15/9/2004 14:05

Gyrus Group (GYG):
Unlike European Diamonds, Gyrus is shown to be overbought in the short term, as the 14 day RSI is at 73. However, while bulls of the stock may be justified in waiting for a dip in the share price, everything else seems to be pointing to a very positive longer term outlook. Both the 50 day and 200 day moving averages are both rising and the shares have multiple touch points at the October support line. Therefore one would back Gyrus to break clearly above the high of the year above 250p seen this time last year. The target for those wishing to buy now is as high as the February 2003 resistance line target near 320p. Only a two day close below the 50 day moving average / 2003 support line at 207p would suggest that we have seen the best of the post December recovery. The weekly close stop loss for long term shareholders is the 200 day moving average at 196p.



Zak Mir is one of Britain's best known chartists, having appeared numerous times on Bloomberg TV and CNBC as well as having written for UK-iNvest, thestreet.co.uk and Shares magazine. Two years ago he set up his own website called Zaks-TA.com which is the UK's only pure TA website, covering everything from small caps to blue-chips to forex, indices and commodities. For more details of this unique site click here

[bullandbear] 14/9/2004 13:02

yep still in gyg..

[zapa] 13/9/2004 20:53

HCEG looks interesting.They have a disposable endoscope(spelling?) coming to market soon.Also their Ebiox hand cleaner (MRSA combatant)is becoming more recognised.

Anyhow,thanks again I am still in GYG so will look in from time to time.

Dave.

[maddox] 13/9/2004 19:24

Zapa,

That’s mightily kind of you. I’ve felt myself somewhat of a lone voice, not that I've seen anything do dampen my enthusiasm for GYG - apart from the lack of recognition that its received for its considerable achievements.

Nevertheless, we’ve got a long way to go. My primary concern is that it will become a takeover target before we reap the full rewards from what I expect to be an extended period of supernormal growth.

Regards, Maddox

[bullandbear] 13/9/2004 17:34

up she goes .. hoping for more movement 2morrow

[zapa] 13/9/2004 14:33

Youve been right all along Maddox.Thank you.

[bullandbear] 13/9/2004 13:59

this has been bubbling over the last week going up from 2.21. Now if this break though the 2.50 mark which I think it will, it will move back to £3.00 a share very easily.. Great company which to me is now ready to move north

[maddox] 10/9/2004 17:15

Bainsey,

The revenue figures are already released with a y-o-y 14% increase to above £42m. So the current buying is ahead of a known decent set of results. We can also expect to see strong cash flow figures and a substantial reduction in debt. The question is might we see a maiden dividend?

As well as this, an article in the Independent reports - the shares rose 5.5p to 226.5p on talk that sales of the group's PlasmaKinetic surgical product are booming. Gyrus Bulls reckon sales are running about 20 per cent ahead of management expectations.

Gyrus'progress has been masked by the dollar's fall - most sales being in the US. If their sales are accelerating this factor will work itself out unless the dollar falls further. On the otherhand if it recovers then it will work to flatter their future results.

Regards, Maddox

[johnroger] 09/9/2004 10:12

Results on 21st expected to be good

[bainsey] 09/9/2004 08:16

any reason for price rise?

[johnroger] 14/7/2004 11:05

LONDON (AFX) - Gyrus Group PLC said it expects first half pretax profits to
be in line with market expectations, as it reported strong sales growth in the
six months to June 30 2004.
In a pre-close period statement, the supplier of medical devices which
reduce trauma and complications in surgery, said sterling revenues were up 14
pct to over 42 mln stg in the first half -- or over 25 pct higher on a constant
currency basis.
And Gyrus said it continued to be strongly cash generative during the period
with net debt reducing substantially from the year-end position.
Strong trading in both the Surgical and Partnered Technologies Divisions
offset lower growth in the ENT Division, the company said.
In the ENT division, Gyrus said that it is developing a marketing strategy
which takes into account the importance of the audiologist in prescribing its
RetroX hearing aid product -- as its sales force is predominantly
surgeon-focused.
The group continues to invest in R&D, both internally and through
in-licensing, with new product developments progressing well.
It is on target to release the Head and Neck surgery workstation --
particularly useful in the removal of tonsils and adenoids -- at year-end.
"To have delivered excellent underlying sales growth and cash generation is
evidence of the strength of the group's portfolio and allows us to continue to
lay sound R&D foundations for our future growth," commented Brian Steer,
executive chairman.
Interim results will be announced on Sept 21.

[bainsey] 19/3/2004 13:21

Gyrus Group, the medical devices specialist, added 8½p at 191p as Panmure Gordon repeated its buy stance and 260p target ahead of prelims on March 29.

[felix99] 18/3/2004 20:12

LIkewise. Very heavy volume today and can;t see any reason why. Bought some - lets see what happens but appears there must be something brewing.

[ok,yah] 18/3/2004 08:15

Just got back in this morning as looks cheap and seems to be attracting a lot of interest

[maddox] 17/3/2004 21:34

Hi Zapa,

Yep, still in but disappointed by the recent price performance. However, the story is one of long term solid above average growth so I'm staying put. The damn thing charges away and then gradually falls back - if I had more time to spend I'd probably be playing the peaks and troughs.

Regards, Maddox

[zapa] 17/3/2004 20:17

Maddox you still in?

[phil7c] 15/2/2004 12:37

HL Inside the City has GYG as a buy (12/2/04) - standard analysis covering all operations. Nothing new but a persuasively written half page+ article.

[tedg41] 13/2/2004 08:32

Yes. Lets hope we have reached the turning point.

[johnroger] 12/2/2004 21:17

Lloyds stake expresses confidence in the company

[johnroger] 29/1/2004 21:43

pacman88 .... thanks for posting the broker notes

[pacman88] 29/1/2004 16:02

www.evbg.com 29 January 2004
Gyrus Group (GYG) Add (unchanged)
Mkt cap:
£157m
Net cash: £-16m Trading update Price/Target: 189p/192p
Pre-close statement – in-line with (revised) expectations
As expected, currency remains an issue for Gyrus – 80% of the group's
revenue is denominated in US dollars – but the underlying businesses
appear to be showing growth.
We took the opportunity yesterday to highlight what we thought would be
the key issues in this morning's pre-close statement...and as we thought,
Gyrus has been keen to emphasise its underlying business in the face of US
dollar weakness. In terms of the revisions we made to current year forecasts,
our assumptions on currency appear to be pretty much correct – Gyrus
anticipates revenues for the year to be c£78m, delivering profit before tax
and amortisation of c£8.0m. According to Gyrus, global sales of the RetroX
system are 'approaching' $1m – on translation this would appear to match
our estimate of c£0.5m pretty well.
In addition to RetroX, Gyrus has highlighted progress in three other areas,
noting the role of new product introductions. The Diego Microdebrider
product (mechanical tissue removal) has supported strong growth in Sinus
and Rhinology. Gynaecology has seen strong growth on the back of the
company's PK (PlasmaKinetic) Systems, including the PK Open Forceps
product. Finally, increased revenue has been seen in the partnered business
with the introduction of VAPR III to Mitek (J&J).
So what are our thoughts on the trading outlook? Well, we'd agree that the
underlying businesses appear to be moving in the right direction. However,
with the dollar showing no sign of strengthening in the near-term, this will
continue to be the single major issue for Gyrus to deal with. Dilution of the
relative contribution of US-denominated revenues should help, but will also
take time. We've noted the strategy of building a presence in Europe, but the
immediate situation still remains one of US-exposure.